NCT02247843View on ClinicalTrials.gov

Stem Cell Gene Therapy for Sickle Cell Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

βAS3-FB vector transduced peripheral blood CD34+ cells

CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.

Trial Locations (1)

90095

University of California, Los Angeles (UCLA), Los Angeles

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Donald B. Kohn, M.D.

OTHER

NCT02247843 - Stem Cell Gene Therapy for Sickle Cell Disease | Biotech Hunter | Biotech Hunter